Alumis Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.2%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$3.32next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| NDA Submission for Envudeucitinib in Plaque Psoriasis | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Envudeucitinib (ESK-001) PASI 90 Response Rate at Week 24 Annually6,500.0%Target: Maintain or exceed 60% in long-term extension studies
Cash, Cash Equivalents, and Marketable Securities Quarterly569.5MTarget: Sufficient to fund operations into Q4 2027
Quarterly Research and Development (R&D) Expenses Quarterly81.5MTarget: Manage burn rate post-Phase 3 ONWARD completion
Watch Items
- New Drug Application (NDA) Submission for Envudeucitinib in Plaque PsoriasisTrigger: Submission timeline target of Q4 2026Action: Monitor FDA acceptance of filing and potential advisory committee meetings
- Phase 2b LUMUS Trial Topline Data in Systemic Lupus Erythematosus (SLE)Trigger: Data readout expected in Q3 2026Action: Evaluate efficacy signals and safety profile to determine pivotal Phase 3 design
- Strategic Alternatives for Lonigutamab ProgramTrigger: Decision to out-license, partner, or divest the assetAction: Track business development updates and potential upfront cash inflows
Research as of 19 Jun 2026